Work

I-103 The absence of drug resistance against dolutegravir in first-line therapy is attributable to reduced viral replicative fitness

Year: 2017

Type: conference-abstract

Source: JAIDS Journal of Acquired Immune Deficiency Syndromes

DOI: 10.1097/01.qai.0000513875.61517.23

Author: Mark Wainberg

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W2599254898

Cites:

Cited by:

Related to: 10